Home » Stocks » ATHX

Athersys, Inc. (ATHX)

Stock Price: $1.83 USD -0.02 (-1.08%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $1.80 -0.03 (-1.64%) Mar 8, 7:03 PM
Market Cap 360.80M
Revenue (ttm) 457,000
Net Income (ttm) -66.48M
Shares Out 197.34M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $1.83
Previous Close $1.85
Change ($) -0.02
Change (%) -1.08%
Day's Open 1.89
Day's Range 1.79 - 1.94
Day's Volume 2,405,381
52-Week Range 1.13 - 4.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 6 days ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.

Business Wire - 2 weeks ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.

Business Wire - 2 weeks ago

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys

Seeking Alpha - 1 month ago

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

Business Wire - 1 month ago

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.

Zacks Investment Research - 2 months ago

Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

The Motley Fool - 2 months ago

The biotech announced the enrollment of the first patient in a key clinical study.

Business Wire - 2 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic inju...

Business Wire - 3 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.

Seeking Alpha - 3 months ago

Athersys has taken its time in developing an interesting pipeline which has potential to offer outsized rewards. Athersys' US timeline for its ischemic stroke indication keeps challenging inve...

Seeking Alpha - 3 months ago

Athersys, Inc.'s (ATHX) CEO Gil Van Bokkelen on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen On Q3 2020 Results - Quick Version Earnings Call Transcript

Business Wire - 3 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications

Business Wire - 5 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020.

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Zacks Investment Research - 5 months ago

The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.

Business Wire - 5 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA.

Seeking Alpha - 6 months ago

Athersys: Still An Abundance Of Opportunity

Seeking Alpha - 6 months ago

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q2 2020 Results - Earnings Call Transcript

Business Wire - 6 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial comp...

Business Wire - 7 months ago

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.

The Motley Fool - 8 months ago

The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.

The Motley Fool - 8 months ago

The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.

Seeking Alpha - 9 months ago

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

Other stocks mentioned: CMRX, CTSO, CYDY, MESO
Seeking Alpha - 9 months ago

Athersys: Fare Well

Seeking Alpha - 10 months ago

Athersys Inc.s' (ATHX) CEO Gil Van Bokkelen on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 10 months ago

The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?

The Motley Fool - 10 months ago

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.

Other stocks mentioned: MESO, PSTI
Seeking Alpha - 10 months ago

Athersys: Abundance Of Opportunity

The Motley Fool - 10 months ago

The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.

Zacks Investment Research - 10 months ago

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Other stocks mentioned: GILD, JNJ, MESO, PFE, PSTI, REGN
Benzinga - 10 months ago

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Other stocks mentioned: BCRX, BIOC, CANF
Market Watch - 10 months ago

Shares of Athersys Inc. ATHX, -2.02% shot up 26.5% in premarket trading Monday, after the company said it has received Food and Drug Administration authorization to start a phase 2/3 trial to ...

Seeking Alpha - 11 months ago

Athersys Inc.: MultiStem Cell Therapy Is The Most Advanced And Tested Treatment For ARDS, And Thus COVID-19

Seeking Alpha - 11 months ago

Athersys - Now In Play For COVID-19 - FDA Fast Tracked Therapy For ARDS

Seeking Alpha - 11 months ago

Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Athersys And The Law Of Large Numbers

Seeking Alpha - 1 year ago

Athersys & The Law Of Large Numbers

GlobeNewsWire - 1 year ago

Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® Highly experienced pharmaceutic...

GlobeNewsWire - 1 year ago

One-year results support positive 28-day findings and suggest further benefits for ARDS patients One-year results support positive 28-day findings and suggest further benefits for ARDS patients

GlobeNewsWire - 1 year ago

Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan

Seeking Alpha - 1 year ago

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available

Seeking Alpha - 1 year ago

We review significant developments in the last three months in our the stem cell triple play and how they create value moving forward.

Other stocks mentioned: AVMXY
Seeking Alpha - 1 year ago

I will give a quick overview of Athersys and their MultiStem product.

Seeking Alpha - 1 year ago

Athersys, Inc. (ATHX) on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Understanding the basics of the stem cell sector.

Other stocks mentioned: AVMXY, CYTX
Seeking Alpha - 1 year ago

Hypoxia is a core problem in stroke and other ischemic injuries.

Other stocks mentioned: BIIB
The Motley Fool - 1 year ago

The FDA has given the company's lead drug platform a potential leg up in development.

Seeking Alpha - 1 year ago

ATHX is developing a stem cell therapy that enlarges the window of treatment for ischemic strokes.

About ATHX

Athersys, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Pha... [Read more...]

Industry
Biotechnology
Founded
1995
CEO
Gil Van Bokkelen
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
ATHX
Full Company Profile

Financial Performance

In 2019, Athersys's revenue was $5.63 million, a decrease of -76.81% compared to the previous year's $24.29 million. Losses were -$44.58 million, 83.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Athersys stock is "Strong Buy." The 12-month stock price forecast is 6.80, which is an increase of 271.58% from the latest price.

Price Target
$6.80
(271.58% upside)
Analyst Consensus: Strong Buy